scispace - formally typeset
G

Giulia Malaguarnera

Researcher at University of Catania

Publications -  104
Citations -  4516

Giulia Malaguarnera is an academic researcher from University of Catania. The author has contributed to research in topics: Cancer & Hepatocellular carcinoma. The author has an hindex of 35, co-authored 101 publications receiving 3790 citations. Previous affiliations of Giulia Malaguarnera include UCL Institute of Ophthalmology.

Papers
More filters
Journal ArticleDOI

Preserved transcallosal inhibition to transcranial magnetic stimulation in nondemented elderly patients with leukoaraiosis.

TL;DR: Transcallosal inhibitory mechanisms to TMS seem to be spared in LA patients, a finding which is in line with neuroimaging features and suggests a functional integrity of the CC despite the ischemic interruption of corticosubcortical loops implicated in cognition and behavior.
Journal ArticleDOI

Resveratrol in Patients with Minimal Hepatic Encephalopathy

TL;DR: Resveratrol showed efficacy in the treatment of depression, anxiety, and ammonia serum levels, and improved the quality of life of MHE patients.
Journal ArticleDOI

Markers of bile duct tumors

TL;DR: This review aims to introduce the main features of the most important serum and molecular markers of biliary tree tumors.
Journal ArticleDOI

TMS follow-up study in patients with vascular cognitive impairment-no dementia.

TL;DR: This study represents the first evidence of a decrease of the median resting motor threshold in VCI-ND patients during the progression of cognitive impairment, and might be considered an index of motor cortex plasticity and interpreted as a compensatory mechanism for the loss ofMotor cortex neurons.
Journal ArticleDOI

The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies

TL;DR: Treatment strategies combining blockade of immunoregulatory cell types such as Tregs and MDSCs and of inhibitory receptors, with vaccine-induced activation of TAA-specific T cells, may be necessary to achieve the most effective therapeutic antitumour activity in HCC.